Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for
Sanofi India Ltd
-(SANOFI)
XNSE:SANOFI, XBOM:SANOFI
Sanofi India Ltd Q4FY24; 28% fall in Profits
Sanofi India is engaged in Business of Manufacture and sale of pharmaceutical products. Financial Results: Sanofi India Ltd reported Revenues for Q4FY24
Sanofi India Ltd Q3FY24; 5% rise in Profits
Sanofi India is engaged in Business of Manufacture and sale of pharmaceutical products. Financial Results: Sanofi India Ltd reported Revenues for Q3FY24
Sanofi India Ltd Q2FY24; 16% rise in Profits
Sanofi India is engaged in Business of Manufacture and sale of pharmaceutical products. Financial Results: Sanofi India Ltd reported Revenues for Q2FY24
Sanofi India Ltd Q1FY24; 2% rise in Profits
Sanofi India is engaged in Business of Manufacture and sale of pharmaceutical products. Financial Results: Sanofi India Ltd reported Revenues for Q1FY24
Sanofi India Ltd (SANOFI) Q4 FY23 Earnings Concall Transcript
Sanofi India Ltd (NSE:SANOFI) Q4 FY23 Earnings Concall dated May. 11, 2023. Corporate Participants: Radhika Kartik Shah -- Company Secretary and Compliance Officer Rodolfo
Sanofi Ltd Q4FY23 results out, revenue soars by 4%
Sanofi India is engaged in Business of Manufacture and sale of pharmaceutical products. Company has three brands (Lantus, Allegra, Combiflam) in top
Sanofi India Limited Q3FY23 Earnings Story
Sanofi India primarily deals with the Manufacture and sale of pharmaceutical products. Financial Results: The company reported a decline of 2.32% YoY
Sanofi India Ltd Q4 CY21 Earnings Conference Call Insights
https://youtu.be/D2vfw6hB5RI Key highlights from Sanofi India Ltd (SANOFI) Q4 CY21 Earnings Concall Q&A Highlights: Vipul Shah of RippleWave Equity asked if the
Sanofi India Ltd (SANOFI) Q4 FY21 Earnings Concall
Sanofi India Ltd (NSE:SANOFI) Q4 FY21 Earnings Concall dated Mar. 02, 2022